Karyopharm Therapeutics Inc.
KPTIDrugs in Pipeline
10
Phase 3 Programs
5
Upcoming Catalysts
10
Next Catalyst
Aug 10, 2026
27dMarket Overview
Stock performance and key metrics
10 upcoming, 1 past
How KPTI's past catalysts played out
Ruxolitinib
Myelofibrosis
Selinexor (combination therapy)
Relapsed/Refractory Diffuse Large B-cell Lymphoma
Bortezomib
Multiple Myeloma
Dexamethasone
Multiple Myeloma
Selinexor
Multiple Myeloma, Refractory
KPT-8602
Relapsed/Refractory Multiple Myeloma (RRMM)
Selinexor 60 mg
Myelofibrosis
Hydroxyurea
Acute Myeloid Leukemia (AML)
Selinexor 100 mg
Non-Small Cell Lung Carcinoma (NSCLC)
Lenalidomide
Multiple Myeloma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ruxolitinib | Phase 3 | Myelofibrosis | - | - |
Selinexor (combination therapy) | Phase 3 | Relapsed/Refractory Diffuse Large B-cell Lymphoma | - | - |
Bortezomib | Phase 3 | Multiple Myeloma | - | - |
Dexamethasone | Phase 3 | Multiple Myeloma | - | - |
Selinexor | Phase 3 | Multiple Myeloma, Refractory | - | - |
KPT-8602 | Phase 2 | Relapsed/Refractory Multiple Myeloma (RRMM) | - | - |
Selinexor 60 mg | Phase 2 | Myelofibrosis | - | - |
Hydroxyurea | Phase 2 | Acute Myeloid Leukemia (AML) | - | - |
Selinexor 100 mg | Phase 2 | Non-Small Cell Lung Carcinoma (NSCLC) | - | - |
Lenalidomide | Phase 2 | Multiple Myeloma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Karyopharm Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 10 drug candidates in Karyopharm Therapeutics Inc.'s (KPTI) pipeline across Phase 3, Phase 2. Its lead program is Ruxolitinib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Karyopharm Therapeutics Inc.'s next FDA catalyst?→
Karyopharm Therapeutics Inc.'s (KPTI) next tracked catalyst is a Phase 3 expected June 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KPTI biotech catalysts?→
Add KPTI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Karyopharm Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.